Roche starts late-stage trial for eye drug lampalizumab

[September 15, 2014]  ZURICH (Reuters) - Swiss drugmaker Roche said on Monday it had started late-stage trials for its experimental drug lampalizumab as a treatment for a serious eye disease.

The Basel-based firm has initiated Phase III trials for lampalizumab as a treatment for geographic atrophy, a leading cause of blindness in adults over 55, which gradually causes vision loss in the macula, making it harder to read, drive and recognise people's faces.

(Reporting by Caroline Copley)

[© 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.